Testing the safety of WEF-001 for KRAS-mutant cancers
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing clinical trials.
This trial studies a new drug called WEF-001 for people with advanced cancers that have a KRAS mutation. It aims to see if the drug is safe and shrinks tumors when used alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these cancer types: pancreatic, colorectal, lung, ovarian, bile duct, or bladder cancer
- Your tumor has a KRAS mutation, which will be checked by a test
- Your cancer has gotten worse after at least one previous standard treatment
- You are in good enough health to be up and about (ECOG score 0 or 1)
- No active infections, serious heart problems, or untreated brain tumors
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called LT-010391 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The drug is designed to target this mutation, and the study aims to see if it can help when standard treatments are no longer working.
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
This trial tests a new drug called MR001, which is designed to help your immune system fight cancer, in people with advanced solid tumors that have not responded to other treatments. It may be an option if standard treatments have stopped working or caused too many side effects.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This study tests an experimental drug (RX001) given directly into tumors for people with advanced lung cancer that has a KRAS mutation. It is a phase 1 trial, so the main goal is to check safety and find a good dose.
This early-stage trial tests a new drug called INV-8989 designed to target a specific genetic mutation (KRAS G12D) found in some advanced solid cancers. The study will evaluate whether the drug is safe and if it can help shrink tumors in patients who haven't responded to standard treatments.
Hear when a new Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.